Welcome to the new and improved Apricus Biosciences, Inc. website. We believe that the website’s enhancements re-affirm our commitment to open communications with shareholders, and will serve as a useful resource for patients and healthcare providers. I invite you to explore our site for frequently updated information on our Company, obtain helpful information in our new resource center, or read periodic updates on our progress here, in my CEO message.
Since the beginning of 2013, we continue to make progress on the successful execution of our corporate goals, including gaining European regulatory approval for Vitaros®, licensing the un-partnered Vitaros® territories in Europe, obtaining regulatory feedback from the FDA on Femprox®, extending our cash runway and divesting all non-strategic assets.
Looking forward, our top priorities are to secure additional Vitaros® partnerships this quarter, support our commercialization partners’ launch of Vitaros® in 2014, and move Femprox®, our product candidate for female sexual interest/arousal disorder (“FSIAD”) into the clinic with a development partner in 2014. I look forward to updating you on our progress on each of these initiatives as they develop.
Thank you for your continued support and as always if you have questions, please do not hesitate to contact our Investor Relations team.
Richard W. Pascoe Chief Executive Officer
Forward-Looking Statement Safe Harbor
With the exception of the historical information, the matters described herein contain forward-looking statements that involve risks and uncertainties may cause actual results to differ materially from the anticipated future results discussed above. These include risks relating to our ability to secure additional partnerships for Vitaros, the timing and success of launch of Vitaros (where approved), our ability to gain additional regulatory approvals for Vitaros and the timing and ability to commence clinical development of Femprox. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in our most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Our product, Vitaros®, is a topical cream for the treatment of erectile dysfunction. Vitaros® is locally applied and contains alprostadil plus our novel excipient.
Femprox® is in development for the treatment of Female Sexual Dysfunction or FSD. Like Vitaros®, Femprox® is a cream designed for local application and composed of alprostadil and our novel excipient.
We partner with world-class pharmaceutical
companies who share our passion for improving
men’s and women’s sexual health.